Essential Hypertension

Cardiovascular
25
Pipeline Programs
10
Companies
27
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
2
0
16
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 26 programs with unclassified modality

On Market (2)

Approved therapies currently available

U
ATENOLOLApproved
atenolol
Unknown Company
oral1991
U
BENICARApproved
olmesartan medoxomil
Unknown Company
oral2002

Competitive Landscape

7 companies ranked by most advanced pipeline stage

DS
Daiichi SankyoChina - Shanghai
15 programs
1
11
2
AtenololPhase 4Small Molecule1 trial
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryPhase 41 trial
CS-3150Phase 31 trial
CS8635 20/5/12.5mg and placeboPhase 31 trial
Olmesartan medoxomilPhase 31 trial
+10 more programs
Active Trials
NCT02848170Completed40Est. Apr 2017
NCT02345044Completed426Est. Oct 2015
NCT02722265Completed368Est. Jul 2017
+12 more trials
Celltrion
CelltrionKorea - Incheon
3 programs
1
1
AZM X mg + AML Y mgPhase 31 trial
L04RD1Phase 11 trial
Azilsartan MedoxomilN/A1 trial
Active Trials
NCT04470817Completed3,438Est. May 2023
NCT05993806Completed50Est. Jun 2023
NCT05385770Completed890Est. Jul 2024
Takeda
TakedaTOKYO, Japan
2 programs
2
Azilsartan medoxomil and chlorthalidonePhase 31 trial
TAK-536TCH tabletPhase 31 trial
Active Trials
NCT00996281Completed837Est. Nov 2011
NCT02277691Completed341Est. Apr 2016
DP
Daehwa PharmaceuticalKorea - Gangwon
1 program
1
AGSAVIPhase 31 trial
Active Trials
NCT05503953Unknown306Est. Jul 2024
Pfizer
PfizerNEW YORK, NY
1 program
1
olmesartan alone or in combination with hydrochlorothiazidePhase 31 trial
Active Trials
NCT00139698Completed410Est. Jul 2006
Genomics
GenomicsUK - Oxford
3 programs
2
1
QGC001Phase 21 trial
QGC001 [Phase 11 trial
QGC001 [Phase 11 trial
Active Trials
NCT01900171Completed56Est. May 2012
NCT01900184Completed69Est. Mar 2013
NCT02322450Completed34Est. Apr 2016
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
In-practice Evaluation of Atacand 16mg Antihypertensive EffectN/A1 trial
The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.N/A1 trial
Active Trials
NCT00802542Completed400Est. Jan 2009
NCT01295021Completed1,514Est. Feb 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Daiichi SankyoAtenolol
Daiichi Sankyoolmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
Daehwa PharmaceuticalAGSAVI
CelltrionAZM X mg + AML Y mg
Daiichi SankyoCS-3150
TakedaTAK-536TCH tablet
Daiichi SankyoCS8635 20/5/12.5mg and placebo
TakedaAzilsartan medoxomil and chlorthalidone
Daiichi Sankyoolmesartan medoxomil + amlodipine + hydroclororthiazide + placebo
Daiichi SankyoOlmesartan medoxomil 40 mg - Amlodipine 10 mg
Daiichi Sankyoolmesartan medoxomil
Daiichi Sankyoolmesartan medoxomil
Daiichi Sankyoolmesartan medoxomil + hydrochlorothiazide
Pfizerolmesartan alone or in combination with hydrochlorothiazide
Daiichi Sankyoolmesartan medoxomil

Showing 15 of 27 trials with date data

Clinical Trials (27)

Total enrollment: 18,389 patients across 27 trials

NCT01132768Daiichi SankyoAtenolol

The Confirmatory Olmesartan Plaque Regression Study

Start: May 2010Est. completion: Jun 2011114 patients
Phase 4Terminated
NCT00890591Daiichi Sankyoolmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

Start: Aug 2006Est. completion: Aug 2007144 patients
Phase 4Completed
NCT05503953Daehwa PharmaceuticalAGSAVI

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

Start: Sep 2022Est. completion: Jul 2024306 patients
Phase 3Unknown
NCT05385770CelltrionAZM X mg + AML Y mg

Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

Start: Jul 2022Est. completion: Jul 2024890 patients
Phase 3Completed
NCT02722265Daiichi SankyoCS-3150

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Start: Mar 2016Est. completion: Jul 2017368 patients
Phase 3Completed
NCT02277691TakedaTAK-536TCH tablet

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

Start: Nov 2014Est. completion: Apr 2016341 patients
Phase 3Completed
NCT01838850Daiichi SankyoCS8635 20/5/12.5mg and placebo

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy

Start: Apr 2013Est. completion: Aug 2014344 patients
Phase 3Completed
NCT00996281TakedaAzilsartan medoxomil and chlorthalidone

Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

Start: Oct 2009Est. completion: Nov 2011837 patients
Phase 3Completed
NCT00923091Daiichi Sankyoolmesartan medoxomil + amlodipine + hydroclororthiazide + placebo

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Start: Jun 2009Est. completion: Mar 20112,689 patients
Phase 3Completed
NCT00902538Daiichi SankyoOlmesartan medoxomil 40 mg - Amlodipine 10 mg

Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension

Start: Apr 2009Est. completion: Oct 20102,204 patients
Phase 3Completed
NCT00430508Daiichi Sankyoolmesartan medoxomil

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Start: Feb 2007Est. completion: May 2008972 patients
Phase 3Completed
NCT00430950Daiichi Sankyoolmesartan medoxomil

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Start: Feb 2007Est. completion: Oct 20081,011 patients
Phase 3Completed
NCT00872586Daiichi Sankyoolmesartan medoxomil + hydrochlorothiazide

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

Start: Aug 2006Est. completion: Aug 2007304 patients
Phase 3Completed
NCT00139698Pfizerolmesartan alone or in combination with hydrochlorothiazide

Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension

Start: Sep 2005Est. completion: Jul 2006410 patients
Phase 3Completed
NCT00220220Daiichi Sankyoolmesartan medoxomil

Amlodipine as add-on to Olmesartan in Hypertension

Start: Apr 2005Est. completion: Apr 2007429 patients
Phase 3Completed
NCT00151827Daiichi SankyoOlmesartan medoxomil

Olmesartan Medoxomil in Hypertension and Renal Impairment

Start: Aug 2003Est. completion: Jul 2005393 patients
Phase 3Completed
NCT00751751Daiichi Sankyoolmesartan medoxomil + hydrochlorothiazide, if necessary

Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly

Start: Jun 2003Est. completion: Jun 2005441 patients
Phase 3Completed
NCT00185185Daiichi SankyoOlmesartan medoxomil

Olmesartan Medoxomil in Atherosclerosis

Start: Nov 2001Est. completion: Feb 2006165 patients
Phase 3Completed
NCT02345044Daiichi SankyoCS-3150

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

Start: Jan 2015Est. completion: Oct 2015426 patients
Phase 2Completed
NCT02322450GenomicsQGC001

Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension

Start: Jan 2015Est. completion: Apr 201634 patients
Phase 2Completed
NCT05993806CelltrionL04RD1

A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers

Start: Jun 2023Est. completion: Jun 202350 patients
Phase 1Completed
NCT01900184GenomicsQGC001 [

Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects

Start: Dec 2012Est. completion: Mar 201369 patients
Phase 1Completed
NCT01900171GenomicsQGC001 [

Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo

Start: Feb 2012Est. completion: May 201256 patients
Phase 1Completed
NCT04470817CelltrionAzilsartan Medoxomil

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Start: Aug 2018Est. completion: May 20233,438 patients
N/ACompleted
NCT02848170Daiichi SankyoCS-3150

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Start: Aug 2016Est. completion: Apr 201740 patients
N/ACompleted
NCT01295021AstraZenecaThe Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.

The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.

Start: Feb 2011Est. completion: Feb 20121,514 patients
N/ACompleted
NCT00802542AstraZenecaIn-practice Evaluation of Atacand 16mg Antihypertensive Effect

In-practice Evaluation of Atacand 16mg Antihypertensive Effect

Start: Nov 2008Est. completion: Jan 2009400 patients
N/ACompleted

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
19h ago
From $150K/yr

Clinical Consultant

Johnson & Johnson
North Ryde, New South Wales, Australia
20h ago

Regional Sales Specialist (Orange County / Long Beach, CA) - Johnson & Johnson MedTech, Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
20h ago
$100K - $135K/yr

Trainee Technical Specialist

Johnson & Johnson
Leeds, West Yorkshire, United Kingdom
20h ago

Ingénieur d'Application Clinique (H/F) Dept. 54, 57, 67, 68, 25, 90

Johnson & Johnson
Issy-les-Moulineaux, France
20h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

16 late-stage (Phase 3) programs — potential near-term approvals
10 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Coronary Heart Disease(28)Aortic Valve Stenosis(27)Atherosclerosis(27)